Oncotarget

Research Papers:

Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor

Xing Yang _, Il Minn, Steven P. Rowe, Sangeeta Ray Banerjee, Michael A. Gorin, Mary Brummet, Hye Soo Lee, Soo Min Koo, Polina Sysa-Shah, Ronnie C. Mease, Sridhar Nimmagadda, Mohamad E. Allaf and Martin G. Pomper

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:33733-33742. https://doi.org/10.18632/oncotarget.5254

Metrics: PDF 1297 views  |   HTML 1484 views  |   ?  


Abstract

Xing Yang1,*, Il Minn1,*, Steven P. Rowe1, Sangeeta Ray Banerjee1, Michael A. Gorin2, Mary Brummet1, Hye Soo Lee1, Soo Min Koo1, Polina Sysa-Shah1, Ronnie C. Mease1, Sridhar Nimmagadda1, Mohamad E. Allaf2, Martin G. Pomper1

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

*These authors have contributed equally to this work

Correspondence to:

Martin G. Pomper, e-mail: mpomper@jhmi.edu

Xing Yang, e-mail: xyang45@jhmi.edu

Keywords: CAIX, single photon emission computed tomography, molecular imaging, renal cell carcinoma, indium-111

Received: May 31, 2015     Accepted: September 03, 2015     Published: September 16, 2015

ABSTRACT

We developed a new scaffold for radionuclide-based imaging and therapy of clear cell renal cell carcinoma (ccRCC) targeting carbonic anhydrase IX (CAIX). Compound XYIMSR-01, a DOTA-conjugated, bivalent, low-molecular-weight ligand, has two moieties that target two separate sites on CAIX, imparting high affinity. We synthesized [111In]XYIMSR-01 in 73.8–75.8% (n = 3) yield with specific radioactivities ranging from 118 – 1,021 GBq/μmol (3,200–27,600 Ci/mmol). Single photon emission computed tomography of [111In]XYIMSR-01 in immunocompromised mice bearing CAIX-expressing SK-RC-52 tumors revealed radiotracer uptake in tumor as early as 1 h post-injection. Biodistribution studies demonstrated 26% injected dose per gram of radioactivity within tumor at 1 h. Tumor-to-blood, muscle and kidney ratios were 178.1 ± 145.4, 68.4 ± 29.0 and 1.7 ± 1.2, respectively, at 24 h post-injection. Retention of radioactivity was exclusively observed in tumors by 48 h, the latest time point evaluated. The dual targeting strategy to engage CAIX enabled specific detection of ccRCC in this xenograft model, with pharmacokinetics surpassing those of previously described radionuclide-based probes against CAIX.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5254